Abstract
HBsAg decline >0.5 log10 at week 12 (40% vs 4%, p = 0.03) or >1 log10 at week 24 (40% vs 0%, p = 0.004). Conclusions: In HBeAg-negative CHB patients, a significant mean decline in HBsAg levels from baseline was first observed at 24 weeks of treatment with peginterferon-alfa-2a. Early HBsAg decline is associated with on-treatment virological response, while its potential associations with post-treatment responses remain to be evaluated.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
